Waisenmedizin e. V. Promoting Access to Essential Medicine Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2004
NCT00947362
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

Waisenmedzin eV PACEM non-profit German NGO

Active Ingredients

Drugs in Phase 3 Trials (2)

dac n-055 (2 trials)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (1)

sodium stibogluconate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3